Concert Pharma (CNCE) Reports Q4 Loss of $0.69/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Concert Pharmaceuticals Reports 2020 Financial Results and Provides Update on Clinical Programs
February 25, 2021 7:00 AM ESTCTP-543 Phase 3 Program Advancing in Alopecia Areata; THRIVE-AA2, the Second CTP543 Phase 3 Trial, to Initiate 1H2021
CTP-543 Long-Term Data Presented at EADV Show Hair Regrowth was Maintained or Improved in Patients with Alopecia Areata, Expanding Previous Phase 2 Results
Conference Call and Webcast Scheduled Today at 8:30 a.m. ET
LEXINGTON, Mass.--(BUSINESS... More
